Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review

References

• Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018;180:206–216.
   PubMed Web of Science ®Google Scholar
• Yu L, Tu M, Cortes J, et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017;129:1658–1668.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am. 2018;32:11–21.
   PubMed Web of Science ®Google Scholar
• Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74:1360–1367.
   PubMed Web of Science ®Google Scholar
• van Gameren MM, Willemse PH, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I–II study. Blood. 1994;84:1434–1441.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15:966–974.
   PubMed Web of Science ®Google Scholar
• Neipel F, Albrecht JC, Ensser A, et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol. 1997;71:839–842.
   PubMed Web of Science ®Google Scholar
• Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman’s disease. Am J Pathol. 1997;151:1517–1522.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627–2632.
   PubMed Web of Science ®Google Scholar
• Song S-NJ, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116:3627–3634.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010;28:3701–3708.
   PubMed Web of Science ®Google Scholar
• Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Intern Med. 2007;46:771–774.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013;19:3659–3670.
   PubMed Web of Science ®Google Scholar
• Shimojima Y, Takei Y, Tazawa K, et al. Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman’s disease. Amyloid. 2006;13:184–186.
   PubMed Web of Science ®Google Scholar
• Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–1280.
   PubMed Web of Science ®Google Scholar
• Dupin N, Gorin I, Deleuze J, et al. Herpes-like DNA sequences, AIDS-related tumors, and Castleman’s disease. N Engl J Med. 1995;333:798; author reply 798–799.
   PubMed Web of Science ®Google Scholar
• Veldhuis GJ, van der Leest AH, de Wolf JT, et al. A case of localized Castleman’s disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol. 1996;73:47–50.
   PubMed Web of Science ®Google Scholar
• Vinzio S, Ciarloni L, Schlienger J-L, et al. Isolated microcytic anemia disclosing a unicentric Castleman disease: the interleukin-6/hepcidin pathway? Eur J Intern Med. 2008;19:367–369.
   PubMed Web of Science ®Google Scholar
• van der Hilst JCH, Yamada T, Op den Camp HJM, et al. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology. 2008;47:1651–1654.
   PubMed Web of Science ®Google Scholar
• Obici L, Raimondi S, Lavatelli F, et al. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum. 2009;61:1435–1440.
   PubMed Web of Science ®Google Scholar
• Noh OK, Lee S-W, Lee JW, et al. Cases report of unicentric Castleman's disease: revisit of radiotherapy role. Radiat Oncol J. 2013;31:48–54.
   PubMedGoogle Scholar
• Rhee F, van Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132:2115–2124.
   PubMed Web of Science ®Google Scholar